Denosumab helps improve BMD in hyperparathyroidism
The antiresorptive agent denosumab, used alone or in combination with the calcimimetic agent cinacalcet, improves BMD and reduces bone turnover in patients with primary hyperparathyroidism (PHPT) — providing a potential treatment option for patients in whom surgery is undesirable, the DENOCINA* trials has shown.
